In preclinical studies, a small-molecule activator of lymphocyte function-associated antigen 1 showed potential for transforming “cold” tumors into “hot” ones that are more responsive to immunotherapy. (University of Texas MD Anderson Cancer Center, Journal of Clinical Investigation)
Helper T cells (CD4+) may have a bigger role in immune-system activity against cancer than previously recognized. (Washington State University, Journal of Immunology)
A therapy platform that uses ultrasound-guided microbubbles to prime the immune system has shown promise for improving tumor responses to immunotherapy. (University of Texas MD Anderson Cancer Center)
New research into the link between diabetes and breast cancer suggests that evolving cancer causes insulin resistance and impaired blood-sugar regulation, which then feeds the cancer. (University of California San Diego)
With summer nearing full swing, some facts, advice, and myths about sun exposure, sunscreens, tanning, and skin cancer. (MedStar Health)
Novartis announced FDA approval of the CAR T-cell product tisagenlecleucel (Kymriah) for relapsed/refractory follicular lymphoma in adults.
Bristol Myers Squibb announced FDA approval of nivolumab (Opdivo) plus chemotherapy, and nivolumab plus ipilimumab (Yervoy), as first-line treatment for unresectable advanced or metastatic esophageal squamous cell carcinoma.
Amneal Pharmaceuticals announced FDA approval of pegfilgrastim-pbbk (Fylnetra), a biosimilar to Neulasta.
The cancer vaccine RV001 (onilcamotide) failed to slow prostate cancer progression after biochemical recurrence in a phase II placebo-controlled trial, RhoVac announced.
Plant-based diets may offer benefits for several types of chronic diseases, including cancer. (American Journal of Lifestyle Medicine)
The herbal supplement berberine may have a role in preventing and treating lung cancer. (University of Technology Sydney)
Synthetic forms of PPARδ, often found in unregulated performance-enhancing supplements, may increase the risk for pancreatic cancer. (University of Michigan, Nature Communications)
-
Charles Bankhead is senior editor for oncology and also covers urology, dermatology, and ophthalmology. He joined MedPage Today in 2007. Follow
Please enable JavaScript to view the